Stop Monitoring Patents Manually — The Alert You Missed Last Quarter Already Cost You the Window
On July 22, 2026, Organon received a Paragraph IV certification notice from Encube Ethical Private Limited, disclosing a generic filing
Your Biosimilar Interchangeability Assumption Is Costing You a Full Formulary Cycle
Biocon’s aflibercept biosimilar Yesafili became one of the first two products in its category to earn the FDA’s interchangeable designation
Your Biosimilar Interchangeability Assumption Is Costing You a Full Formulary Cycle Read Post »
The Settlement Everyone Calls a “Win” Usually Means the Brand Bought Two More Years Cheaper Than Trial
On May 18, 2026, a federal jury in Boston awarded purchasers of Amitiza (lubiprostone) $884,943,990 in single damages against Takeda,
No Generic Waiting in the Wings: Why the Gene Therapy Patent Cliff Isn’t a Small-Molecule Patent Cliff
Casgevy lists for $2.2 million a dose. Lyfgenia lists for $3.1 million. Lenmeldy launched at roughly $4.25 million, the highest
The First Filer Doesn’t Always Keep the 180 Days: The Forfeiture Triggers Nobody Tracks
On August 25, 2026, the D.C. Circuit told the FDA it had been reading its own forfeiture statute wrong for
The First Filer Doesn’t Always Keep the 180 Days: The Forfeiture Triggers Nobody Tracks Read Post »
The PTAB’s Pharma Paradox: Why Drug-Patent Denials Are Rising Even as the Topline Number Holds
On July 24, 2025, the Acting Director of the U.S. Patent and Trademark Office denied two of Amgen’s three petitions
The Trial You Win Can Still Break Your Balance Sheet: What 15 Years of Latisse Litigation Teaches Generic Drugmakers
The Short Answer A courtroom win in Hatch-Waxman litigation only resolves the specific patent claims that went to trial. It
The File Wrapper Problem: Why “We’ll Settle Before Trial” Stops Working Once Someone Reads Your Prosecution History
On May 13, 2026, the Federal Circuit closed out a patent fight that had already run for more than six
The Next Patent Cliff Isn’t Small Molecules — It’s the First Wave of Approved Cell and Gene Therapies
Zolgensma’s seven-year orphan drug exclusivity expired in May 2026. Novartis has faced this moment for a year without a single
